Functionally enhanced siRNA targeting TNFα attenuates dss-induced colitis and TLR-mediated immunostimulation in mice

Molecular Therapy

Volumn 20, Issue 2, 2012, Pages 382-390

  Ocampo, Sandra M ^a,b,c   Romero, Carolina ^d   Avĩó, Anna ^b,e   Burguẽo, Joan ^d   Gassull, Miguel A ^f   Bermúdez, Jordi ^c   Eritja, Ramon ^a,b,e   Fernandez, Ester ^d   Perales, Jose C ^c  

^a INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA IQAC CSIC   (Spain)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^f Germans Trias i Pujol Foundation   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2' O METHYL AND PROPANEDIOL MODIFIED SMALL INTERFERING RNA; 2' O METHYL MODIFIED SMALL INTERFERING RNA; AQUAPORIN 4; CLAUDIN 7; CRABP2 PROTEIN; CYTOKERATIN 4; DEXTRAN SULFATE; DOUBLE STRANDED RNA; GA733 PROTEIN; GLYCOPROTEIN; LIPOFECTAMINE; LOCKED NUCLEIC ACID AND PROPANEDIOL MODIFIED SMALL INTERFERING RNA; MUCIN 1; MUCIN 2; MYELOPEROXIDASE; NUCLEASE; PHOSPHOROTHIOATE AND PROPANEDIOL MODIFIED SMALL INTERFERING RNA; PROPANEDIOL MODIFIED SMALL INTERFERING RNA; PROTEIN; PROTEIN SHH 2; SMALL INTERFERING RNA; SONIC HEDGEHOG PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHEMICAL MODIFICATION; COLITIS; COLON; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; DRUG EFFICACY; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE SILENCING; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY INFILTRATE; INNATE IMMUNITY; INTESTINE CRYPT; LIPOSOMAL GENE DELIVERY SYSTEM; MOUSE; NEUTROPHIL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RNA DEGRADATION; RNA STABILITY; SURVIVAL RATE; TUMOR NECROSIS FACTOR ALPHA GENE; UPREGULATION; WEIGHT TO LENGTH COLON RATIO;

ANIMALIA; MURINAE; MUS;

EID: 84856544764     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.236     Document Type: Article

References (50)

1. Jung, HC, Eckmann, L, Yang, SK, Panja, A, Fierer, J, Morzycka-Wroblewska, E et al. (1995). A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest 95: 55-65.
2. Plevy, SE, Landers, CJ, Prehn, J, Carramanzana, NM, Deem, RL, Shealy, D et al. (1997). A role for TNF-and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 159: 6276-6282. (Pubitemid 127471570)
3. Van Deventer, SJ (1997). Tumour necrosis factor and Crohn's disease. Gut 40: 443-448. (Pubitemid 27204920)
4. Papadakis, KA and Targan, SR (2000). Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51: 289-298. (Pubitemid 30216038)
5. Prehn, JL, Landers, CJ and Targan, SR (1999). A soluble factor produced by lamina propria mononuclear cells is required for TNF-enhancement of IFN-production by T cells. J Immunol 163: 4277-4283. (Pubitemid 29474493)
6. Funakoshi, K, Sugimura, K, Anezaki, K, Bannai, H, Ishizuka, K and Asakura, H (1998). Spectrum of cytokine gene expression in intestinal mucosal lesions of Crohn's disease and ulcerative colitis. Digestion 59: 73-78. (Pubitemid 28022450)
7. Komatsu, M, Kobayashi, D, Saito, K, Furuya, D, Yagihashi, A, Araake, H et al. (2001). Tumor necrosis factor-αin serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem 47: 1297-1301. (Pubitemid 32579119)
8. Murch, SH, Braegger, CP, Walker-Smith, JA and MacDonald, TT (1993). Location of tumour necrosis factor by immunohistochemistry in chronic inflammatory bowel disease. Gut 34: 1705-1709. (Pubitemid 23353163)
9. Woywodt, A, Ludwig, D, Neustock, P, Kruse, A, Schwarting, K, Jantschek, G et al. (1999). Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol 11: 267-276. (Pubitemid 29286680)
10. Dieleman, LA, Ridwan, BU, Tennyson, GS, Beagley, KW, Bucy, RP and Elson, CO (1994). Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107: 1643-1652. (Pubitemid 24357616)
11. Neurath, MF, Fuss, I, Pasparakis, M, Alexopoulou, L, Haralambous, S, Meyer zum Büschenfelde, KH et al. (1997). Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 27: 1743-1750. (Pubitemid 27302858)
12. Gitter, AH, Bendfeldt, K, Schmitz, H, Schulzke, JD, Bentzel, CJ and Fromm, M (2000). Epithelial barrier defects in HT-29/B6 colonic cell monolayers induced by tumor necrosis factor-?. Ann N Y Acad Sci 915: 193-203. (Pubitemid 32059380)
13. Marano, CW, Lewis, SA, Garulacan, LA, Soler, AP and Mullin, JM (1998). Tumor necrosis factor-αincreases sodium and chloride conductance across the tight junction of CACO-2 BBE, a human intestinal epithelial cell line. J Membr Biol 161: 263-274. (Pubitemid 28085051)
14. Böcker, U (2000). Cytokines and cell homeostasis in the gastrointestinal tract. Lancaster.
15. Myers, KJ, Murthy, S, Flanigan, A, Witchell, DR, Butler, M, Murray, S et al. (2003). Antisense oligonucleotide blockade of tumor necrosis factor-αin two murine models of colitis. J Pharmacol Exp Ther 304: 411-424. (Pubitemid 36008955)
16. Powrie, F, Leach, MW, Mauze, S, Menon, S, Caddle, LB and Coffman, RL (1994). Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1: 553-562.
17. Hartmann, G, Bidlingmaier, C, Siegmund, B, Albrich, S, Schulze, J, Tschoep, K et al. (2000). Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther 292: 22-30. (Pubitemid 30026352)
18. Keane, J, Gershon, S, Wise, RP, Mirabile-Levens, E, Kasznica, J, Schwieterman, WD et al. (2001). Tuberculosis associated with infliximab, a tumor necrosis factor-neutralizing agent. N Engl J Med 345: 1098-1104.
19. Sandborn, WJ and Hanauer, SB (1999). Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 5: 119-133.
20. Brown, SL, Greene, MH, Gershon, SK, Edwards, ET and Braun, MM (2002). Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46: 3151-3158. (Pubitemid 35453523)
21. Zuo, L, Huang, Z, Dong, L, Xu, L, Zhu, Y, Zeng, K et al. (2010). Targeting delivery of anti-TNF αoligonucleotide into activated colonic macrophages protects against experimental colitis. Gut 59: 470-479.
22. Sidiropoulos, P, Liu, H, Mungre, S, Anderson, L, Thimmapaya, B and Pope, RM (2001). Efficacy of adenoviral TNF antisense is enhanced by a macrophage specific promoter. Gene Ther 8: 223-231. (Pubitemid 32186134)
23. Yacyshyn, B, Bowen-Yacyshyn, MB and Shanahan, W (1999). The clinical experience of antisense therapy to ICAM-1 in Crohn's disease. Curr Opin Mol Ther 1: 332-335. (Pubitemid 29309181)
24. Layzer, JM, McCaffrey, AP, Tanner, AK, Huang, Z, Kay, MA and Sullenger, BA (2004). In vivo activity of nuclease-resistant siRNAs. RNA 10: 766-771. (Pubitemid 38529739)
25. Kriegel, C and Amiji, M (2011). Oral TNF-a gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J Control Release 150: 77-86.
26. Sørensen, DR, Leirdal, M and Sioud, M (2003). Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 327: 761-766. (Pubitemid 36315917)
27. Aerschot, AS-BT, Rozenski, J, Hendrix, C, Schepers, D, Verhoeven, G, and Herdewijn, P (1995). Conjugation of oligonucleotides to 3'-polar moieties. Bull Soc Chim Belg 104: 717-720.
28. Jackson, AL and Linsley, PS (2010). Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9: 57-67.
29. Corazza, N, Brunner, T, Buri, C, Rihs, S, Imboden, MA, Seibold, I et al. (2004). Transmembrane tumor necrosis factor is a potent inducer of colitis even in the absence of its secreted form. Gastroenterology 127: 816-825. (Pubitemid 39208414)
30. Zhang, Y, Cristofaro, P, Silbermann, R, Pusch, O, Boden, D, Konkin, T et al. (2006). Engineering mucosal RNA interference in vivo. Mol Ther 14: 336-342. (Pubitemid 44184961)
31. Herdewijn, P, Saison-Behmoaras, E, Van Aerschot, A, Leserman, L, Eritja, R and Pfleiderer, W (1998). Antisense oligonucleotides as anticancer agents. Biomedical and Health Research 24: 182-189.
32. Eder, PS, DeVine, RJ, Dagle, JM and Walder, JA (1991). Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3' exonuclease in plasma. Antisense Res Dev 1: 141-151.
33. Olson, AD, DelBuono, EA, Bitar, KN and Remick, DG (1995). Antiserum to tumor necrosis factor and failure to prevent murine colitis. J Pediatr Gastroenterol Nutr 21: 410-418.
34. Kojouharoff, G, Hans, W, Obermeier, F, Männel, DN, Andus, T, Schölmerich, J et al. (1997). Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 107: 353-358. (Pubitemid 27049264)
35. Noti, M, Corazza, N, Mueller, C, Berger, B and Brunner, T (2010). TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis. J Exp Med 207: 1057-1066.
36. Naito, Y, Takagi, T, Handa, O, Ishikawa, T, Nakagawa, S, Yamaguchi, T et al. (2003). Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-αdeficient mice. J Gastroenterol Hepatol 18: 560-569. (Pubitemid 36645291)
37. Kassiotis, G and Kollias, G (2001). Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 193: 427-434. (Pubitemid 32524474)
38. Suzuki, R, Miyamoto, S, Yasui, Y, Sugie, S and Tanaka, T (2007). Global gene expression analysis of the mouse colonic mucosa treated with azoxymethane and dextran sodium sulfate. BMC Cancer 7: 84.
39. Gao, D, Wagner, AH, Fankhaenel, S, Stojanovic, T, Schweyer, S, Panzner, S et al. (2005). CD40 antisense oligonucleotide inhibition of trinitrobenzene sulphonic acid induced rat colitis. Gut 54: 70-77. (Pubitemid 40007220)
40. Vijay-Kumar, M, Wu, H, Aitken, J, Kolachala, VL, Neish, AS, Sitaraman, SV et al. (2007). Activation of toll-like receptor 3 protects against DSS-induced acute colitis. Inflamm Bowel Dis 13: 856-864. (Pubitemid 47203863)
41. Cekaite, L, Furset, G, Hovig, E and Sioud, M (2007). Gene expression analysis in blood cells in response to unmodified and 2'-modified siRNAs reveals TLR-dependent and independent effects. J Mol Biol 365: 90-108. (Pubitemid 44830036)
42. Choung, S, Kim, YJ, Kim, S, Park, HO and Choi, YC (2006). Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun 342: 919-927. (Pubitemid 43320485)
43. Robbins, M, Judge, A, Liang, L, McClintock, K, Yaworski, E and MacLachlan, I (2007). 2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther 15: 1663-1669. (Pubitemid 47289010)
44. Karikó, K, Buckstein, M, Ni, H and Weissman, D (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23: 165-175. (Pubitemid 41169286)
45. Salomon, W, Bulock, K, Lapierre, J, Pavco, P, Woolf, T and Kamens, J (2010). Modified dsRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC. Nucleic Acids Res 38: 3771-3779.
46. Aviñó, A, Güimil Garcia, R, Albericio, F, Mann, M, Wilm, M, Neubauer, G et al. (1996). New carbamate supports for the preparation of 3'-amino-modified oligonucleotides. Bioorg Med Chem 4: 1649-1658. (Pubitemid 26361869)
47. Cooper, HS, Murthy, SN, Shah, RS and Sedergran, DJ (1993). Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249.
48. Krawisz, JE, Sharon, P and Stenson, WF (1984). Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87: 1344-1350. (Pubitemid 15201434)
49. Dieleman, LA, Palmen, MJ, Akol, H, Bloemena, E, Peña, AS, Meuwissen, SG et al. (1998). Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114: 385-391. (Pubitemid 28539597)
50. Auer, H, Newsom, DL, Nowak, NJ, McHugh, KM, Singh, S, Yu, CY et al. (2007). Generesolution analysis of DNA copy number variation using oligonucleotide expression microarrays. BMC Genomics 8: 111.